iSpecimen Inc.
$0.13
▼
-6.45%
2026-04-21 07:36:00
ispecimen.com
NCM: ISPC
Explore iSpecimen Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.05 M
Current Price
$0.13
52W High / Low
$3.18 / $0.1
Stock P/E
—
Book Value
$0.31
Dividend Yield
—
ROCE
-355.55%
ROE
-3.28%
Face Value
—
EPS
$-2.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
7
Beta
1.98
Debt / Equity
8.7
Current Ratio
1.12
Quick Ratio
1.12
Forward P/E
-0.16
Price / Sales
1.97
Enterprise Value
$-2.81 M
EV / EBITDA
0.32
EV / Revenue
-1.46
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Twist Bioscience Corporation | $61.88 | — | $3.79 B | — | -24.75% | -16.79% | $62.09 / $23.3 | $7.44 |
| 2. | XWELL, Inc. | $1.2 | — | $9.7 M | — | -75.03% | -275.96% | $2.2 / $0.26 | $-1.1 |
| 3. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
| 4. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 5. | Castle Biosciences, Inc. | $25.16 | — | $744.77 M | — | -8.4% | -5.21% | $44.28 / $14.59 | $15.86 |
| 6. | Insight Molecular Diagnostics Inc. | $3.99 | — | $128.35 M | — | -223.51% | 229.65% | $8.51 / $2.33 | $-1.1 |
| 7. | Exagen Inc. | $2.99 | — | $72.61 M | — | -32.08% | -1.48% | $12.23 / $2.59 | $0.76 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.05 M | 0.11 M | 0.71 M | 1.06 M | 1.48 M | — |
| Operating Profit | -2.69 M | -2.83 M | -1.82 M | -1.64 M | -5.84 M | — |
| Net Profit | -5 M | -2.78 M | -1.05 M | -1.66 M | -6.05 M | — |
| EPS in Rs | -0.17 | -0.09 | -0.04 | -0.06 | -0.2 | -2.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.93 M | 9.29 M | 9.93 M | 10.4 M |
| Operating Profit | -8.98 M | -12.73 M | -11.17 M | -10.19 M |
| Net Profit | -10.49 M | -12.5 M | -11.1 M | -10.25 M |
| EPS in Rs | -0.35 | -0.42 | -0.37 | -0.35 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.53 M | 9.35 M | 15.82 M | 24.62 M |
| Total Liabilities | 6.44 M | 6.04 M | 6.08 M | 4.31 M |
| Equity | 3.09 M | 3.31 M | 9.74 M | 20.31 M |
| Current Assets | 6.95 M | 3.59 M | 8.24 M | 19.68 M |
| Current Liabilities | 6.23 M | 5.77 M | 6.05 M | 4.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.24 M | -8.26 M | -5.81 M | -5.82 M |
| Investing CF | -1 M | 1.98 M | -7.23 M | -3.19 M |
| Financing CF | 10.24 M | 5.82 M | 0.07 M | -3.42 M |
| Free CF | -5.24 M | -8.97 M | -10.55 M | -9.01 M |
| Capex | -1 M | -0.71 M | -4.74 M | -3.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.42% | -4.56% | — | — |
| Earnings Growth % | -12.6% | -8.33% | — | — |
| Profit Margin % | -134.51% | -111.8% | -98.5% | — |
| Operating Margin % | -136.99% | -112.5% | -97.92% | — |
| Gross Margin % | 42.93% | 51.45% | 54.27% | — |
| EBITDA Margin % | -107.45% | -88.17% | -84.61% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-16 | 1:0.05 |